ClinicalTrials.gg
Sign In
TerminatedNCT07927803Updated Nov 10, 2026

Targeted Minimally-Invasive Glaucoma Surgery

An interventional study of Excimer Laser Trabeculostomy (ELT) and Excimer Laser Trabeculostomy (ELT) in Open Angle Glaucoma (OAG), sponsored by Johannes Kepler University of Linz. Terminated at 1 site in Austria. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Johannes Kepler University of Linz · Not applicable, Interventional, and Treatment

Why this study was terminated
insufficient effect size at planned interim analysis

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Oct 2024, registered Nov 2026).
Updated Nov 10, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

MIGS procedures are currently performed without targeting a specific region of the outflow pathway. The temporal surgical approach means that treatment is delivered to the nasal quadrant. Preclinical analyses have shown that targeted treatment of low-flow regions of the trabecular meshwork can improve efficacy. The aim of this study is to use aqueous angiography to guide the placement of an established MIGS procedure, excimer laser trabeculostomy (ELT; Elios Vision GmbH), in order to improve its efficacy.

02

Conditions studied

  • Open Angle Glaucoma (OAG)

Browse trials for

03

In context

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.

This study's enrollment of 37 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Johannes Kepler University of Linz is the lead sponsor of 33 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age equal to or above 45 years
  • written
  • Cataract with indication for surgery
  • preperimetric to moderate open-angle glaucoma
  • central corneal thickness 480-620µm
  • availability, willingness and ability to understand and give consent to study participation

Exclusion criteria

Exclusion Criteria:

  • participation in another interventional study
  • previous glaucoma surgery
  • previous selective laser trabeculoplasty
  • ambiguous glaucoma diagnosis
  • ocular hypertension
  • corneal pathology with influence on intraocular pressure measurement
  • inflammatory ocular disease
  • increases risk for intraoperative floppy iris syndrome
  • medical interventions planned in parallel, that interfere with the study intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Other
    High-Flow ELT

    Procedure: Excimer Laser Trabeculostomy (ELT)

  • Other
    Low-Flow ELT

    Procedure: Excimer Laser Trabeculostomy (ELT)

Interventions

  • ProcedureExcimer Laser Trabeculostomy (ELT)

    ELT in a Aqueous Angiography- defined High Flow Regions

  • ProcedureExcimer Laser Trabeculostomy (ELT)

    ELT in a Aqueous Angiography- defined Low Flow Regions

06

What researchers measure

Primary outcomes

  1. IOP

    Time frame: three months after intervention

  2. number of IOP-lowering medications

    Time frame: three months after intervention

07

Study locations

1 site
  • Kepler University Hospital, Johannes Kepler University
    Linz, Upper Austria 4020, Austria
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the publication will be made available upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jul 2026, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 10, 2026
StartActual
Oct 3, 2024
Primary completionActual
Jul 10, 2026
CompletionActual
Jul 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07927803
Lead sponsor
Johannes Kepler University of Linz
Responsible party
Sponsor
First posted
Nov 10, 2026
Start date
Oct 3, 2024
Primary completion
Jul 10, 2026
Completion
Jul 10, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glaucoma, Open-Angle →

Other studies from this sponsor

Johannes Kepler University of Linz

Start the discussion